Lead Product(s): TMS-007
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TMS-007
Highest Development Status: Phase II Product Type: Small molecule
Deal Size: $353.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 12, 2021
Biogen exercised its option to acquire TMS-007, an investigational drug for acute ischemic stroke, from TMS. Biogen’s decision to acquire TMS-007 was based on positive data from a Phase 2a study.